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The treatment of chronic hepatitis C virus (HCV) genotype
1 infection has been revolutionized by the introduction of
direct-acting antiviral (DAA) agents (boceprevir and telapre-
vir) in combination with peginterferon and ribavirin.
Although improved antiviral efficacy and shorter durations of
therapy are anticipated, there are also potentially severe
drug-drug interactions involving protease inhibitors and
other commonly used agents, and both practitioners and
patients must familiarize themselves with these interactions
before they use these agents.
Drug Metabolism
The cytochrome P450s (CYPs) are a superfamily of genes
composed of several isoenzymes expressed in the endoplas-
mic reticulum of the liver and other organs that are integrally
involved in the oxidative metabolism (i.e., phase 1) of
numerous drugs (Fig. 1). In particular, the CYP3A4 and
CYP3A5 isoenzymes are involved in the metabolism of up to
40% of all marketed drugs.1,2 In addition, the enzyme activ-
ity of CYP3A4 and CYP3A5 in the small intestine can also
influence the bioavailability of some drugs. Multiple studies
have demonstrated substantial interindividual variations (i.e.,
4- to 10-fold) in the hepatic expression of CYP3A4; this can
be explained in part by genetic polymorphisms, diet, and
other environmental cofactors.3 The P-glycoprotein trans-
porter system, which is encoded by the multidrug resistance
protein 2 gene and is localized in the plasma membranes of
hepatocytes and enterocytes, is also involved in the elimina-
tion of various drugs and/or metabolites (i.e., phase 3). This
enzyme family plays a key role in the elimination of many
commonly used drugs and has also been shown to be both
inducible and inhibitable like CYP3A with complex gene
regulation.4
Drugs and herbal agents such as rifampin, efavirenz, and
St. John’s wort are known to induce the expression of
CYP3A4 activity via the activation of nuclear receptors in the
liver and lead to clinically significant reductions in the blood
levels of cyclosporine and other CYP3A4 substrates with
potentially deleterious clinical effects (Table 1).5,6 Con-
versely, other commonly used medications such as alpha-
1-adrenoreceptor antagonists and statins can competitively
inhibit CYP3A4 activity.7 When competitive inhibitors and
substrates of CYP3A4 are coadministered, the drug levels of
one or both agents may significantly increase, and this can
lead to clinically significant drug-drug interactions and asso-
ciated adverse events.
Both telaprevir and boceprevir are extensively metabolized
in the liver and are potent CYP3A4 substrates and inhibitors.
Telaprevir is also a P-glycoprotein substrate and inhibitor,
whereas boceprevir is partially metabolized by hepatic aldo-
keto reductase. Therefore, the coadministration of either of
these agents with other drugs metabolized by CYP3A4 may
lead to increased pharmacokinetic and pharmacodynamic
effects of the other drugs via the competitive inhibition of
their metabolism (Fig. 2). For example, the peak plasma con-
centration (Cmax) for atorvastatin was 10-fold higher when it
was coadministered with telaprevir in healthy volunteers.8 In
addition, Cmax for amlodipine was 1.3-fold higher when it
was coadministered with telaprevir. On the basis of these
results and other in vitro testing, the package inserts for both
protease inhibitors provide lists of drugs that are absolutely
contraindicated when a patient is receiving either agent
because of the potential for serious or life-threatening
adverse events (Table 1).8,9 In addition, other drugs that are
less dependent on CYP3A for elimination (e.g., amlodipine)
should also be administered with caution to subjects
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receiving telaprevir or boceprevir (Table 2). Although addi-
tional prospective studies are needed in HCV patients, boce-
previr-treated patients in clinical trials who received a drug
metabolized by CYP3A did not have an overall increased risk
of an adverse event, although anemia and dysgeusia were
more frequent with selective concomitant medications.10
The serum levels of the DAAs themselves may also be
affected when they are coadministered with certain drugs
(Table 3). For example, the azole antifungal agents, which
are strong binders of CYP3A, are expected to lead to
potentially significant elevations in the serum levels of
both boceprevir and telaprevir. As a result, telaprevir-
treated patients receiving one of these drugs may experi-
ence more frequent or severe rashes, myelotoxicity, or gas-
trointestinal symptoms. Similarly, boceprevir-treated
patients may have more frequent or severe anemia and/or
dysgeusia when they are receiving one of these drugs.
Therefore, practitioners must advise their patients to con-
tact them if they develop an intercurrent illness that may
require treatment and to report all concomitant medica-
tions. In addition, the treating physician may preferentially
select an antibiotic, analgesic, or antidepressant that is less
FIGURE 1. Proportions of commonly used drugs metabolized by CYP
isoenzymes in the human liver.
TABLE 1. Drugs Absolutely Contraindicated With the Prescription of
Telaprevir or Boceprevir Because of Potentially Serious Adverse Events
Drug Class Examples
Potentially Serious
or Life-Threatening
Adverse Events
CYP3A substrates/inhibitors
Alpha-1-adrenoreceptor
antagonists
Alfuzosin Hypotension, dizziness
Ergot derivatives Dihydroergotamine
Ergonovine
Ergotamine
Methylergonovine
Peripheral vasospasm
or ischemia
Gastrointestinal motility
agents
Cisapride Cardiac arrhythmia,
QT prolongation
3-Hydroxy-3-methyl-
glutaryl-coenzyme
A reductase inhibitors
(statins)
Atorvastatin*
Lovastatin
Simvastatin
Myopathy,
rhabdomyolysis
Neuroleptics Pimozide Cardiac arrhythmia
Oral contraceptives† Drospirenone Hyperkalemia
Phosphodiesterase type
5 enzyme inhibitors†
Sildenafil
Tadalafil
Visual abnormalities,
hypotension,
prolonged erection,
syncope
Sedatives Midazolam
Triazolam
Prolonged sedation,
respiratory
depression
CYP3A inducers
Anticonvulsants† Carbamazepine
Phenobarbital
Phenytoin
Reduced DAA levels
with potentially
reduced antiviral
efficacy and
increased drug
resistance
Antimycobacterials Rifampin
Herbal products St. John’s wort
The information in this table was obtained from package inserts for
boceprevir and telaprevir (February 2012).8,9
*For telaprevir only.
†For boceprevir only.
‡Used to treat pulmonary hypertension at high doses.
FIGURE 2. Mechanism for the competitive inhibition of CYP3A enzyme ac-
tivity. (A) Many commonly used drugs such as atorvastatin have a strong bind-
ing affinity for CYP3A4, which is located in the endoplasmic reticulum of hepa-
tocytes. In the steady state, the drug is absorbed via the gastrointestinal tract,
metabolized by CYP3A4 in the liver, and eliminated from the body. (B) When a
drug with a similar or greater binding affinity to CYP3A4 (e.g., telaprevir or
boceprevir) is coadministered with atorvastatin, it can displace atorvastatin
from CYP3A4 and lead to greater local and systemic bioavailability of the
parent compound. Increased bioavailability of the drug can lead to a greater
pharmacodynamic effect (e.g., hypolipidemia) as well as an increased
incidence or severity of adverse events (e.g., myopathy) because of reduced
drug metabolism.
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likely to lead to an interaction with the DAAs according to
their known routes of elimination (Table 4). Similarly, sub-
jects who receive a known CYP3A inducer such as rifam-
pin or phenytoin may experience lower serum levels of
DAAs and may have a greater risk of treatment failure
and/or drug resistance (Fig. 3). Some studies have begun
to explore the use of higher doses of telaprevir (i.e., 1125
mg by mouth three times a day) in human immunodefi-
ciency virus (HIV)–coinfected patients receiving efavirenz, a
CYP3A inducer, or the use of ritonavir boosting, but fur-
ther studies are needed.11
DAAs in Liver Transplant Recipients
Because of the known risk of accelerated fibrosis and graft
failure from recurrent HCV infections, there is a great deal of
interest in using DAAs in combination with peginterferon
and ribavirin in liver transplant recipients. However, the
coadministration of DAAs and calcineurin inhibitors is a very
risky proposition. For example, Cmax for a single dose of
tacrolimus was 9.3-fold higher when it was coadministered
with telaprevir in healthy volunteers, and the half-life was
increased 5-fold.12 In addition, Cmax for cyclosporine was
increased 1.4-fold in healthy volunteers, whereas the half-life
was increased 3.5-fold.
Similar difficulties with immunosuppressive therapy have
previously been reported for HIV-positive transplant recipi-
ents receiving antiretroviral agents that inhibit CYP3A4. For
example, HIV-positive liver transplant recipients receiving
the potent CYP3A inhibitors ritonavir and lopinavir required
as little as 0.5 mg of tacrolimus per week to maintain thera-
peutic trough levels.13,14 These data suggest that although
DAAs are potentially dangerous, their use in liver transplant
recipients with recurrent HCV on calcineurin inhibitors may
TABLE 2. Selected Drugs That Should Be Used With Caution in
Subjects Receiving Boceprevir or Telaprevir Because of Altered
Metabolism
Drug Class Examples Potential Impact
CYP3A substrates
Antiarrhythmics Amiodarone
Digoxin
Lidocaine
Quinidine
Increased arrhythmia
Antidepressants Escitalopram* Decreased efficacy
of antidepressant
Antidepressants Desipramine
Trazodone
Increased sedation,
dry mouth
Azole antifungals Itraconazole
Ketoconazole
Posaconazole
Increased vomiting,
diarrhea, hypertension
Antigout agents Colchicine Increased diarrhea
Calcium channel
blockers
Amlodipine
Diltiazem
Nifedipine
Verapamil
Increased hypotension,
bradycardia
Corticosteroids Budesonide
Fluticasone
Methylprednisolone
Prednisone
Increased hyperglycemia,
osteoporosis, insomnia,
acne
HIV protease inhibitors† Atazanavir Increased vomiting,
diarrhea
HIV reverse transcriptase
inhibitors
Tenofovir Increased nephrotoxicity
Hormonal contraceptives Ethinyl estradiol Decreased efficacy
Immunosuppressants Cyclosporine
Sirolimus
Tacrolimus
Increased nephrotoxicity,
hypertension,
neurotoxicity
Inhaled beta-agonists Salmeterol Increased tachycardia
Macrolide antibiotics Clarithromycin
Erythromycin
Telithromycin
Increased diarrhea,
QT prolongation
CYP3A inducers
HIV protease inhibitors† Atazanavir
Darunavir
Fosamprenavir
Lopinavir
Reduced DAA levels
with potentially
reduced antiviral
efficacy and increased
drug resistanceHIV reverse transcriptase
inhibitors
Efavirenz
Narcotic analgesics Methadone
Sedatives Zolpidem
The information in this table was obtained from package inserts for boce-
previr and telaprevir.8,9
*Only reported with telaprevir.
†When coadministered with ritonavir.
TABLE 3. Drugs That Can Alter Serum Boceprevir and Telaprevir Levels
Drug Class Examples Impact on DAA Level Potential Manifestation of Altered DAA Metabolism
CYP3A substrates
Azole antifungals Itraconazole
Ketoconazole
Posaconazole
Voriconazole
Increase Increased number of adverse events such as rash, myelotoxicity,
and gastrointestinal side effects (telaprevir)
or anemia and dysgeusia (boceprevir)
HIV protease
inhibitors
Atazanavir
Darunavir
Fosamprenavir
Lopinavir
Increase
CYP3A inducers
Anticonvulsants Carbamazepine
Phenobarbital
Phenytoin
Decrease Decreased antiviral efficacy with potential increase in
drug-resistant variants
Antimycobacterials Rifabutin Decrease
Corticosteroids Dexamethasone Decrease
HIV reverse-transcriptase inhibitors Efavirenz Decrease
HIV protease inhibitors* Atazanavir
Darunavir
Fosamprenavir
Lopinavir
Decrease
The information in this table was obtained from package inserts for boceprevir and telaprevir (February 2012).8,9
*When coadministered with ritonavir.
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be possible; however, prospective safety and efficacy studies
will be needed.
Summary Recommendations
It is important that providers carefully review all medica-
tions before and during the treatment of their HCV genotype
1 patients who are receiving boceprevir or telaprevir. Fur-
thermore, the education of patients receiving DAAs must
include explicit instructions to discuss all new medications
with the treating provider in a timely manner. Physicians
must also remember to discontinue both contraindicated and
unnecessary medications when they are initiating therapy
with DAAs. A thorough knowledge of potential drug-drug
interactions (or at least a quickly accessible and updated
database of absolutely and relatively contraindicated drugs)
will also be essential (e.g., www.hep-druginteractions.org or
www.drug-interactions.com). In addition, a list of safe and
effective alternative agents to be used for common ailments
FIGURE 3. Mechanism of CYP3A4 induction and reduced bioavailability of telaprevir/boceprevir. (A) Telaprevir and boceprevir are metabolized in hepatocytes,
which have a constitutive but inducible level of CYP3A4 enzyme activity. (B) The administration of select drugs such as phenytoin and efavirenz can lead to the induc-
tion of additional CYP3A4 gene expression via the activation of intracellular nuclear receptors. This induction leads to greater amounts of CYP3A4 protein expression
in the endoplasmic reticulum, which can lead to enhanced metabolism and the elimination of telaprevir or boceprevir. The net effect of CYP3A4 induction includes a
potential reduction in the local and systemic bioavailability of the DAAs and a higher rate of treatment failure and drug resistance in HCV genotype 1 patients.
TABLE 4. Alternative Agents to Consider for Patients Receiving
Telaprevir or Boceprevir
Antibiotics Amoxicillin
Cefazolin
Clindamycin
Trimethoprim-sulfamethoxazole
Ciprofloxacin
Levofloxacin
Metronidazole
Doxycycline
Analgesics Acetaminophen
Ibuprofen
Tramadol
Oxycodone
Antihypertensives Metoprolol
Hydrochlorothiazide
Lisinopril
Losartan
Clonidine
Antidepressants Bupropion
Duloxetine
Antihistamines Diphenhydramine
Fexofenadine
Antidiabetic agents Metformin
Glipizide
The major metabolism/elimination route of these agents is not CYP3A-
mediated. However, studies of prospective drug-drug interactions with DAAs
in healthy volunteers and/or HCV patients have not been completed.
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and side effects of antiviral therapy that are not expected to
cause drug-drug interactions is needed (Table 4). Lastly,
although there are multiple new DAAs under development
with favorable efficacy and side-effect profiles, the metabo-
lism and elimination of each agent by itself and in combina-
tion with other commonly used drugs will need to be deter-
mined in order to maximize patient safety and optimize clin-
ical outcomes.
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